Downregulation of serum Foxc2 in dilated cardiomyopathy: association with disease severity and cardiac function.

IF 2.1 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-08-29 DOI:10.1080/20565623.2025.2552085

Yufu Cai, Qionghui Huang, Shaobin Zhi, Guixian Guo, Mingfeng Huang, Xiaoyan Tang

{"title":"Downregulation of serum Foxc2 in dilated cardiomyopathy: association with disease severity and cardiac function.","authors":"Yufu Cai, Qionghui Huang, Shaobin Zhi, Guixian Guo, Mingfeng Huang, Xiaoyan Tang","doi":"10.1080/20565623.2025.2552085","DOIUrl":null,"url":null,"abstract":"Background: Dilated cardiomyopathy (DCM) is one of the most frequent non-ischemic causes of heart failure. Foxc2 has been implicated in cardiovascular disease and angiogenesis, but its role in DCM remains undefined. This study aimed to compare serum Foxc2 levels in DCM and non-DCM patients and to assess its clinical relevance.Methods: In this retrospective study, 92 patients (53 DCM, 39 non-DCM) were enrolled. Based on echocardiographic and clinical evaluations, patients were classified into non-DCM group (n = 39) and DCM group (n = 53). Serum Foxc2 concentrations were measured via ELISA, and correlations were analyzed with echocardiographic parameters and biomarkers (BNP, cTnI). ROC analysis assessed Foxc2's diagnostic performance, and Kaplan-Meier analysis evaluated 2-year MACE risk.Results: Serum Foxc2 levels were significantly lower in the DCM group (35.33 ± 27.99 μg/mL vs. 77.51 ± 28.94 μg/mL), and correlated with cardiac function (positive: LVEF, LVFS; negative: LVEDd, BNP, cTnI). ROC analysis demonstrated high diagnostic accuracy for Foxc2 (AUC 0.862). Patients with Foxc2 levels≥ 33.945 μg/mL showed a reduction in 2-year MACE risk (HR 0.187) compared to those with levels below the threshold.Conclusion: Foxc2 may serve as a promising biomarker for DCM diagnosis and prognosis, supporting for further mechanistic investigations.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2552085"},"PeriodicalIF":2.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407816/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20565623.2025.2552085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Dilated cardiomyopathy (DCM) is one of the most frequent non-ischemic causes of heart failure. Foxc2 has been implicated in cardiovascular disease and angiogenesis, but its role in DCM remains undefined. This study aimed to compare serum Foxc2 levels in DCM and non-DCM patients and to assess its clinical relevance.

Methods: In this retrospective study, 92 patients (53 DCM, 39 non-DCM) were enrolled. Based on echocardiographic and clinical evaluations, patients were classified into non-DCM group (n = 39) and DCM group (n = 53). Serum Foxc2 concentrations were measured via ELISA, and correlations were analyzed with echocardiographic parameters and biomarkers (BNP, cTnI). ROC analysis assessed Foxc2's diagnostic performance, and Kaplan-Meier analysis evaluated 2-year MACE risk.

Results: Serum Foxc2 levels were significantly lower in the DCM group (35.33 ± 27.99 μg/mL vs. 77.51 ± 28.94 μg/mL), and correlated with cardiac function (positive: LVEF, LVFS; negative: LVEDd, BNP, cTnI). ROC analysis demonstrated high diagnostic accuracy for Foxc2 (AUC 0.862). Patients with Foxc2 levels≥ 33.945 μg/mL showed a reduction in 2-year MACE risk (HR 0.187) compared to those with levels below the threshold.

Conclusion: Foxc2 may serve as a promising biomarker for DCM diagnosis and prognosis, supporting for further mechanistic investigations.

Abstract Image

查看原文本刊更多论文

扩张型心肌病患者血清Foxc2下调：与疾病严重程度和心功能的关系

背景：扩张型心肌病（DCM）是心衰最常见的非缺血性原因之一。Foxc2与心血管疾病和血管生成有关，但其在DCM中的作用尚不明确。本研究旨在比较DCM和非DCM患者血清Foxc2水平，并评估其临床相关性。方法：回顾性研究92例（DCM 53例，非DCM 39例）。根据超声心动图及临床评价将患者分为非DCM组（n = 39）和DCM组（n = 53）。采用ELISA法测定血清Foxc2浓度，并与超声心动图参数和生物标志物（BNP、cTnI）分析相关性。ROC分析评估Foxc2的诊断表现，Kaplan-Meier分析评估2年MACE风险。结果：DCM组血清Foxc2水平明显降低（35.33±27.99 μg/mL vs. 77.51±28.94 μg/mL），并与心功能相关（阳性：LVEF、LVFS；阴性：LVEDd、BNP、cTnI）。ROC分析显示Foxc2具有较高的诊断准确率（AUC 0.862）。Foxc2水平≥33.945 μg/mL的患者与低于阈值的患者相比，2年MACE风险降低（HR 0.187）。结论：Foxc2可能作为DCM诊断和预后的生物标志物，支持进一步的机制研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.00

自引率

4.00%

发文量

审稿时长

13 weeks

期刊介绍： Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries